EU-Zulassung für Semaglutid-Tablette: 17% Gewichtsverlust, aber strikte Einnahme
The European Medicines Agency (EMA) and regulatory bodies worldwide are closely monitoring the clinical development of oral semaglutide for weight management, a treatment that has demonstrated significant potential in clinical trials such as the OASIS program. While the injectable version of the GLP-1 receptor agonist is already established, the oral formulation requires strict adherence to … Read more